Last reviewed May 10, 2026
Quick answer: The clinical definition of menopause is 12 consecutive months without a period — that's the only line that confirms perimenopause has ended (NAMS, ACOG). Before that line, five signs typically signal you're in late perimenopause: (1) cycles spacing out from 28 days to 60, 90, or 120+ day gaps; (2) hot flashes peaking 1-2 years before the final period and beginning to taper; (3) night sweats easing as estrogen settles low; (4) mood evening out — fewer rage spikes, fewer crash days; and (5) bleeding becoming lighter and more predictable. The STRAW+10 system labels this window "Stage -1." Symptoms don't all disappear at the 12-month line — vaginal dryness, bone loss, and cardiovascular risk rise after menopause, which is why HRT often matters most right at this transition.
The 60-second version
The clinical line: 12 months without a period
There is exactly one number that separates perimenopause from menopause: 12 consecutive months without a menstrual period. The North American Menopause Society and the American College of Obstetricians and Gynecologists both use this definition. Before you cross it, you are in perimenopause — even if you haven't bled in 11 months. After you cross it, you are postmenopausal. There is no other test, no FSH number, no ovary scan that overrides it. One full year. That is the line.
The reason the line is 12 months and not 6 or 8 is not arbitrary. The Stages of Reproductive Aging Workshop (STRAW+10), the international consensus document, picked 12 months because the data show that once a woman has gone a full year without a period, the probability of having another spontaneous period drops to roughly 1-2%. At six months, the probability of a "surprise period" is still 5-10%. Twelve months is the point where the false-finish rate gets low enough that the clinical label changes. Before that, you are still in late perimenopause — STRAW Stage -1 — and the body is still capable of one more ovulation, one more hormonal swing, one more bleed.
The count restarts from any bleed. If you go 9 months with no period and then have a single light bleed, the clock resets to month zero. If you spot for two days at month 11, the clock resets. This is the most disorienting part of the late-perimenopause experience for many women — the finish line keeps moving. Track it on a calendar with a hard date. The 12-month rule is the only thing that ends the perimenopause label.
Sign 1: Your cycles space out — way out
The first and most reliable sign that perimenopause is winding down is that the gaps between periods get long. Not "a few days late." Long. The STRAW+10 staging system defines late perimenopause (Stage -1) as the appearance of at least one interval of 60 or more days of amenorrhea — meaning at least 60 days between periods. SWAN data and follow-up cohorts show this pattern usually begins 1-3 years before the final menstrual period.
The progression most women experience: in early perimenopause, cycles get unpredictable but stay roughly in the 21-35 day range. Then cycles start skipping — you'll have a 60-day gap, then a 35-day gap, then a 90-day gap. By late perimenopause, gaps of 90, 120, even 150 days become common, interleaved with occasional shorter cycles when an ovary still manages to produce a follicle. The variability is the signature. A woman who used to set a calendar by her period ends up not knowing whether the next bleed is six weeks away or three months away.
Where "ending" actually sits on the clinical map
Stage -3 (late reproductive): Cycles still regular but FSH starting to climb in early follicular phase. Most women feel nothing yet.
Stage -2 (early perimenopause): Persistent ≥7-day differences in cycle length. Symptoms often start here — hot flashes, sleep changes, mood swings.
Stage -1 (late perimenopause): At least one interval of 60+ days of amenorrhea. This is "perimenopause is ending." Lasts 1-3 years on average.
Stage +1a (early postmenopause, year 1): First 12 months after the final period. Many symptoms still present.
Stage +1b/+1c (early postmenopause, years 2-6): Symptoms gradually taper for most women.
If you are watching for "is this almost over?" — the 60-day-gap milestone is the most clinically meaningful early answer. Women in STRAW Stage -1 have a roughly 50% chance of being within 2 years of their final menstrual period. That's the closest thing to a countdown the body offers.
Sign 2: Hot flashes peak then taper
Hot flashes have a specific shape across the menopause transition that is poorly understood by most women going through them. They don't appear, stay constant, then disappear. They build, peak, and taper. The peak intensity for most women lands in the 1-2 years before the final period and the 1-2 years after — meaning the worst hot flash years often coincide with the late perimenopause Stage -1 window described above. After the peak, frequency and intensity gradually decline for most women.
The Study of Women's Health Across the Nation (SWAN) — Avis et al. 2015 in JAMA Internal Medicine — followed 1,449 women through the menopause transition and documented that the median total duration of frequent hot flashes is approximately 7.4 years, with the heaviest concentration of severity centered on the final menstrual period. Roughly half of women experienced them for more than 4 years after the final period, and a smaller subset (about 9%) had hot flashes lasting 10+ years. So "they taper" is true on average, but the timeline is longer than the cultural narrative implies.
The signal that perimenopause is ending is not "no more hot flashes" — it is "the hot flashes I had at 49 are noticeably less intense at 51, and the night ones are coming further apart." Many women describe the late-perimenopause shift as the flashes losing their teeth. They still happen. They no longer dominate the day. If you're tracking severity on a 1-10 scale and the average drops from a 7 to a 4 over 6-12 months, that is the taper, and that is consistent with the body settling toward the final period.
Sign 3: Sleep stops fighting back
For most women, the worst sleep of perimenopause lands in the same window as the worst hot flashes — late perimenopause, the 1-2 years before the final period. The mechanism is mechanical: hot flashes that wake you briefly without forming a conscious memory shred slow-wave (deep) sleep, and the estrogen-progesterone volatility that drives flashes also disrupts sleep architecture independently. As the hormonal environment settles toward a stable low estrogen state in the final perimenopause months, the night sweats decrease and the architectural disruption eases. Many women describe the shift as "I'm sleeping again."
This does not always mean good sleep returns. Two important caveats. First, the genitourinary changes of menopause — vaginal dryness, urinary urgency, occasional nocturia — can keep waking you for a different reason once the hot flashes ease. Second, sleep apnea risk rises substantially during the menopause transition as upper-airway tone changes with declining estrogen, and many women newly snore in their fifties without realizing it. If sleep doesn't return as flashes taper, an at-home sleep apnea screen is worth a conversation. For the deeper mechanism, see our companion piece on perimenopause fatigue.
The signal worth watching: in late perimenopause, when night sweats stop being the dominant night-waking event, that is consistent with the hormonal environment stabilizing toward post-menopause. Better sleep at this stage often shows up before the 12-month line is crossed.
Sign 4: Mood evens out (with caveats)
The mood signature of early-to-mid perimenopause is volatility — sudden rage spikes, weepy mornings, anxiety that arrives without a trigger, the "I don't recognize myself" feeling that women describe in journals and on the SWAN cohort interviews. The mechanism is the rapid swing of estrogen across the cycle, which drives serotonin precursor availability up and down with it. Once estrogen settles into a stable low state in late perimenopause, those swings flatten out — and many women describe a real reduction in the day-to-day mood volatility that defined the previous few years.
The caveat is that "fewer swings" does not always mean "good baseline." For a meaningful subset of women, the new low-estrogen baseline produces a flatter, more persistent low mood — less rage, less crashing, but also less joy and less drive. This is mechanistically distinct from the volatile mood of early perimenopause and clinically more like depression. The Schmidt-Rubinow body of work and subsequent research has documented that perimenopausal women have roughly 2-4× the rate of new-onset depression compared to age-matched premenopausal controls, and that the elevated risk continues into the first few postmenopausal years before declining.
The signal worth watching: volatility decreasing is consistent with perimenopause ending. Persistent low mood warrants the same workup any new depression would — and the answer is often a combination of HRT for the hormonal arm and SSRI/therapy for the depressive arm. Don't let "this must just be menopause" delay the conversation. Many women have both, and treating the hormonal piece often unmasks how much was depression vs. how much was hormonal.
Sign 5: Bleeding patterns get predictable — until the last period
Mid-perimenopause bleeding is often heavy, prolonged, and erratic — anovulatory cycles produce thicker endometrial linings that shed in heavier flows, sometimes with clotting, sometimes lasting 8-10 days. By late perimenopause, this typically settles into a different pattern: lighter, shorter, more spaced-out bleeds. Many women describe it as "brief and almost forgettable." That settling is consistent with the body running out of strong follicular cycles and producing thinner linings between increasingly rare ovulations.
The signal worth watching: in late perimenopause, when bleeds you do have are clearly lighter and shorter than the heavy flows of mid-peri, that is consistent with the runway shortening. The pattern usually goes light-and-spaced for the last 12-18 months before stopping entirely.
Red flag bleeding patterns — call your clinician within the week, not at next year's annual: (1) any bleeding after the 12-month menopause line — including spotting, even one day. ACOG guidance is that postmenopausal bleeding requires endometrial assessment because roughly 9% of cases are endometrial cancer, and earlier diagnosis substantially improves outcomes. (2) Sudden heavy bleeding in late perimenopause — a flow that soaks through a pad an hour, large clots, or bleeding lasting more than 7 days. (3) Bleeding between periods or after intercourse. None of these are normal "perimenopause is ending." All warrant prompt clinical evaluation.
For the deeper picture on this specific concern, see our companion piece on bleeding after menopause.
What "ending" doesn't mean
The 12-month line is a clinical marker, not a symptom finish line. The cultural assumption that crossing it means symptoms disappear is wrong, and is one of the reasons many women stop HRT too early or skip it entirely. Several things actually rise after menopause, even as hot flashes begin to taper:
- Vaginal dryness and genitourinary syndrome of menopause (GSM) typically worsen after the final period, not before. Vaginal tissue thins, lubrication declines, urinary urgency and recurrent UTIs increase. GSM affects roughly 50-70% of postmenopausal women and is progressive without treatment. Local vaginal estrogen — cream, ring, or tablet — is highly effective and considered safe for nearly all women. Our flagship Estrogen + Progesterone Vaginal Cream is one option in this category.
- Bone loss accelerates in the first 5-7 years after the final period. The Endocrine Society documents that women lose roughly 1-2% of bone mineral density per year during this window — substantially faster than the 0.5%/year rate before menopause. This is the timing window where HRT, weight-bearing exercise, calcium, and vitamin D matter most for fracture prevention decades later.
- Cardiovascular risk rises sharply after menopause. LDL cholesterol climbs, central fat distribution increases, insulin sensitivity often declines, and the protective estrogen effect on blood vessels is lost. Women's heart attack rates begin tracking men's only after the menopause transition. This is also the window where the NAMS "timing hypothesis" — that HRT started within 10 years of the final period or before age 60 has a favorable cardiovascular risk/benefit ratio — matters most.
- Brain fog often persists for the first year or two after the final period. The cognitive disruption of perimenopause is well-documented in the SWAN cohort, and it doesn't immediately resolve at the 12-month line. For most women it does gradually improve over postmenopausal years 1-3.
The takeaway: "perimenopause is ending" is a transition into a new phase, not a recovery from a temporary illness. The decisions you make in the 1-2 years on either side of your final period — about HRT, about bone health, about cardiovascular screening — set the trajectory for the next 30 years. This is the window NAMS specifically highlights as the highest-leverage time to have the HRT conversation.
How ClearedRx prescribes HRT for late perimenopause and the menopause transition
ClearedRx is a doctor-supervised HRT service for women, online. You take a one-minute quiz. A licensed physician in our network reviews your symptoms and history within 24 hours. If you are a fit, they prescribe — and your treatment ships to your door, discreetly, the same week. We prescribe both compounded and FDA-approved HRT preparations; the patient picks based on cost, format preference, and clinical fit.
The window where most ClearedRx patients start is exactly the late-perimenopause-to-early-menopause window described in this article — the 1-2 years on either side of the final period, when symptoms peak and when the long-term decisions about bone and cardiovascular health start to matter most. Common starting protocols: transdermal estradiol patch or gel paired with oral micronized progesterone if you have a uterus; oral estradiol with progesterone for women who prefer a pill; or a compounded combined Estrogen + Progesterone Cream for women who prefer the body-cream format. For women with prominent vaginal dryness or urinary symptoms, our Estrogen + Progesterone Vaginal Cream specifically addresses the GSM picture.
Cost framing the way our patients experience it: ClearedRx HRT starts at $49 per month for compounded preparations and $89 per month for FDA-approved generics, all-in (medication, doctor reviews, free shipping in all 50 states). New patients receive 50% off their first month. There are no surprise fees and no insurance paperwork. For broader cost context, our HRT cost comparison walks through every formulation across every channel.
"The clinical definition of menopause — 12 consecutive months of amenorrhea — is a retrospective marker. Patients are best served when the perimenopausal-to-postmenopausal transition is treated as a continuous window for symptom control and long-term risk reduction, not as a binary event." — Adapted from The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
If you also want to map the rest of the picture
The end of perimenopause rarely arrives as a single clean signal — most women cross the 12-month line while still managing some combination of hot flashes, sleep changes, mood shifts, and the early genitourinary picture. Mapping the constellation is the cheapest diagnostic move you can make before deciding on a treatment lever. Our free Menopause Symptom Score is a 60-second self-check that scores the cluster as a single hormonal-fingerprint number. For broader context, see our perimenopause vs menopause piece for the full stage-by-stage map, our when to start HRT piece for the timing-window decision, our HRT timeline piece for what to expect in the first weeks, and our bleeding after menopause piece for the red-flag picture in detail.
Common questions
How do I know perimenopause is almost over?
The clinical definition is 12 consecutive months without a menstrual period — that single benchmark, set by NAMS and ACOG, is the line that separates perimenopause from menopause. Before that line, the five signs perimenopause is winding down are: cycles spacing out from a typical 28-35 days to 60, 90, or even 120+ day gaps; hot flashes peaking 1-2 years before the final period and then tapering; night sweats and sleep disruption easing as estrogen settles low; mood volatility flattening out; and bleeding patterns becoming lighter and more predictable. The STRAW+10 staging system labels this window "Stage -1" (late perimenopause). One full year of no period is the only clinical confirmation.
When can I stop birth control?
Pregnancy is still possible during late perimenopause, even with cycles 90+ days apart, because the occasional ovulation still happens. ACOG guidance is that contraception should continue until 12 months without a period if you are 50 or older, or until 24 months without a period if you are under 50. The shift to spaced-out cycles does not by itself mean you can stop contraception. Many women bridge this period with a low-dose continuous oral contraceptive or a hormonal IUD, both of which double as bleeding control and contraception until the 12-month menopause line is crossed.
Will hot flashes ever stop?
For most women, yes — but the timeline is longer than the cultural expectation. The Study of Women's Health Across the Nation (SWAN; Avis et al. 2015) documented that the median total duration of frequent vasomotor symptoms is approximately 7.4 years, with about half of women experiencing them for more than 4 years after the final menstrual period. They typically peak in intensity in the 1-2 years before and after the final period, then gradually taper. A subset of women — roughly 9% in SWAN — continues to have hot flashes 10+ years after menopause. HRT remains the most effective treatment for women whose flashes don't taper on their own.
Should I still take HRT if perimenopause is ending?
Often yes. The "window of opportunity" framing in NAMS guidance is that HRT started within 10 years of the final menstrual period or before age 60 has the best risk/benefit ratio for both symptom control and long-term protection (bone density, cardiovascular risk, urogenital atrophy). "Perimenopause is ending" is not a reason to skip HRT — it is often when symptoms peak and when the long-term prevention conversation matters most. Stopping HRT after a few months of relief is usually the wrong move; bone loss and genitourinary atrophy continue post-menopause, and many women restart within a year.
Is bleeding after menopause normal?
No. Any bleeding — including spotting — after the 12-month no-period menopause line warrants prompt clinical evaluation. ACOG guidance is that postmenopausal bleeding requires endometrial assessment (transvaginal ultrasound for endometrial thickness, often followed by endometrial biopsy) because roughly 9% of postmenopausal bleeding cases are endometrial cancer, and earlier diagnosis substantially improves outcomes. Late-perimenopause sudden heavy bleeding is also a red flag — call your clinician within the week, not at the next annual.
Does perimenopause end suddenly or gradually?
Gradually for most women. The transition from late perimenopause (cycles 60+ days apart) to menopause (12 months no period) is itself usually a 1-3 year process, not a single event. The STRAW+10 staging system labels the late-perimenopause window "Stage -1" and the first year post-final-period "Stage +1a" — and the symptom picture during both is similar. Symptoms don't all disappear at the 12-month line; vaginal dryness, bone loss, and cardiovascular risk actually rise after menopause, even as hot flashes begin to taper.
Sources & references
- Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-1168. PMID: 22344196
- Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539. PMID: 25686030
- The North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PMID: 35797481
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-216. PMID: 24463691
- Kravitz HM, Ganz PA, Bromberger J, et al. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause. 2003;10(1):19-28. PMID: 12544673
- Schmidt PJ, Rubinow DR. Menopause-related affective disorders: a justification for further study. Am J Psychiatry. 1991;148(7):844-852. PMID: 2026136
- ACOG Committee Opinion No. 734: The role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Obstet Gynecol. 2018;131(5):e124-e129. PMID: 29683909
- Endocrine Society. Menopause and Hormone Therapy Clinical Practice Guideline. endocrine.org
- Internal: menopause symptoms overview · menopause symptom score tool · perimenopause vs menopause · when to start HRT · HRT timeline · bleeding after menopause · perimenopause fatigue · HRT cost comparison
If you want to address symptoms and the long-term risk picture together — talk to a clinician
ClearedRx prescribes evidence-based HRT — bioidentical estradiol, progesterone, or a combined cream — based on your full picture, with 24-hour MD review and free shipping in all 50 states. Compounded preparations from $49/month, FDA-approved generics from $89/month. No insurance hassle. New patients save 50% on the first month.
See If HRT Is Right For Me
